WANY
ADAP

Wealthspire Advisors (New York)’s Adaptimmune Therapeutics ADAP Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,750
Closed -$61K – 537
2021
Q3 		$61K Buy
+11,750
New +$52.7K ﹤0.01% 572

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wealthspire Advisors (New York)'s ADAP Position: Q4 2021 in Review

Wealthspire Advisors (New York) sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 11,750 shares — an estimated $61K sold.

Wealthspire Advisors (New York) first reported a position in ADAP in Q3 2021 and held it in 1 quarter. The position peaked at $61K in Q3 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • Wealthspire Advisors (New York) reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 11,750 Adaptimmune Therapeutics shares in Q4 2021, an estimated $61K.
  • Wealthspire Advisors (New York) first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Adaptimmune Therapeutics position peaked at $61K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.